Objective: To compare gene transfer of plasmid (P) and adenovirus (Ad) encoding human vascular endothelial growth factor-A 165 (hVEGF-A 165 ) angiogenic efficacy and adverse effects as regards apoptosis and ectopic expression of the transgene in a rat myocardial infarction model. Methods: Myocardial infarction was provoked in Fisher rats. One week later, PhVEGF-A 165 , PLacZ, AdhVEGF-A 165 , or AdLacZ was transferred intramyocardially along the border of the myocardial infarction. hVEGF-A expression was detected with ELISA. Myocardial vessel density was analyzed 1 and 4 weeks after gene transfer. Apoptosis was detected by TUNEL staining. Cardiac function was assessed with Tissue Doppler Velocity Imaging. Results: Although AdhVEGF-A 165 had substantially higher myocardial hVEGF-A expression than PhVEGF-A 165 , AdhVEGF-A 165 and PhVEGF-A 165 induced angiogenic effects to a similar extent with maintained increased arteriolar density after 4 weeks of gene transfer ( p b 0.05). The two treatments also improved left ventricular function similarly. Adenoviral gene transfer induced a higher number of TUNEL positive cells than plasmid ( p b 0.02). Ectopic expression of the transgene was present with both vectors but substantially higher after adenoviral gene transfer. Conclusions: AdhVEGF-A 165 has no obvious angiogenic advantage over PhVEGF-A 165 but more side effects at least in a rat myocardial infarction model. This indicates that PhVEGF-A 165 might be more applicable for therapeutic angiogenesis than AdhVEGF-A 165 .
Introduction
Transient myocardial overexpression of human vascular endothelial growth factors A (hVEGF-A) by adenovirus (Ad) or plasmid (P) based gene transfer induces angiogenesis both experimentally and in patients with myocardial ischemia [1] . Double-blind randomized and placebo-controlled phase II clinical trials suggest that therapeutic angiogenesis takes place although these studies did not conclusively demonstrate clinical benefits [2] [3] [4] . Both types of vectors have been used in clinical trials for therapeutic angiogenesis. However, their angiogenic efficacy and side effects have not been directly compared in a myocardial infarction model. Adenoviral gene transfer can induce more effective expression of the transgene than plasmid [5, 6] . But it is unclear whether higher intramyocardial hVEGF-A expression level following adenoviral gene transfer also may lead to more pronounced angiogenesis, although continuous retroviral myocardial upregulation of VEGF-A expression was reported to lead to hemangioma formation in immunodeficient mice [7] . Besides, little attention has been paid to potential vector side effects. Adenovirus can modulate apoptosis [8, 9] . When adenovirus is used as gene transfer vector, its structure has been modified [10, 11] . But whether the modified adenovirus or plasmid induces apoptosis that may be harmful to the myocardium remains to be investigated. In addition, differences in the degree of ectopic expression, another safety issue, have not been explored. This study compares the effects of plasmid and adenoviral gene transfer on hVEGF-A expression, angiogenesis, left ventricular function and vector side effects as regards apoptosis and the degree of ectopic transgene expression.
Materials and methods

Adenoviral and plasmid vectors
Human GMP-grade first-generation adenovirus [12] or naked plasmids were used. Both vector types encoded LacZ marker gene or human VEGF-A 165 [13] , driven by a cytomegalo-virus (CMV) immediate early promoter.
In vivo gene transfer
All procedures involving the use and care of animals conform with Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) and was approved by Stockholm Southern Ethics Review Board.
Male Fisher rats (200-250 g) were anaesthetized with midazolam (5 mg/kg) and medetomidine hydrochloride (0.1 mg/kg), and they were intubated and ventilated. The chest was surgically opened through the fourth intercostal space to expose the heart.
Experiment in non-infarcted heart
In order to determine the optimal doses of adenovirus or plasmid, 1 × 10 9 , 5×10 9 , 1×10 10 pfu AdhVEGF-A 165 or 20, 40, 60 μg PhVEGF-A 165 in 100 μl saline was injected intramyocardially into the anterior wall at one spot in the normal heart. There were 5-6 animals in each group. Hearts were harvested to detect hVEGF-A expression 24 h after PhVEGF-A 165 and 6 days after AdhVEGF-A 165 gene transfer. These time points were previously reported to give maximum myocardial expression of the respective vector [14, 15] .
Experiment in infarcted heart
Left anterior descending coronary artery (LAD) was identified and ligated. Pallor and regional wall motion abnormality of the left ventricle confirmed occlusion. Intramyocardial gene transfer was designed to be delivered 1 week after myocardial infarction via a new thoracotomy. Earlier rethoracotomy before 7 days was not permitted by the Ethics Committee and direct delivery after myocardial infarction is not applicable in clinical situation. Treatment at a later time point with progressive cardiac remodeling and cardiomyocyte loss would have less therapeutic effects. Accordingly 7 days was chosen for gene delivery.
Rats were randomly selected for the four treatments. Transferred genes were: AdhVEGF-A 165 (n = 6), AdLacZ (n = 6), PhVEGF-A 165 (n = 6), and PLacZ (n = 7). Rats received 5 ×10 9 pfu adenovirus or 40 μg plasmid in 100 μl saline. A suture was made in the middle area of the myocardial infarction to make a landmark for the injection. Adenovirus or plasmid was injected intramyocardially with an insulin syringe (0.3 mm in diameter) in one spot into the peri-infarction region along the border of the myocardial infarction at the level of the suture (Fig. 1) . Aspiration without retrograde blood filling of the syringe was used as a sign that the needle was in the myocardium but not in the left ventricular cavity. After 1 or 4 weeks animals were euthanized and hearts were collected. Hearts for histological analysis were frozen on OTC compound. Frozen sections were prepared.
Human VEGF-A protein expression
Human VEGF-A gene expression was determined by ELISA in hearts both with and without myocardial infarction. In addition, ectopic hVEGF-A expression was determined in kidney, lung, liver and spleen from the non-infarcted rats. Organs were minced with a homogenizator knife in homogenization buffer. Thereafter the homogenized substance was centrifuged for 10 min at 14,000 ×g rpm at 4°C. The supernatant was collected and frozen at − 70°C. Later all frozen samples were analyzed by ELISA for hVEGF-A by immunoassay according to the manufacturer's instructions (Quantkine, R&D system).
hVEGF expression was visualized in myocardial tissue by immunohistochemistry stained with hVEGF antibody. Frozen sections were incubated with monoclonal antihVEGF-A (Sigma) followed by adding fluorescent-labeled (FITC) secondary antibody.
Endogenous VEGF-A protein expression
Endogenous VEGF was analyzed by ELISA with detection of rat VEGF-A (Quantkine, R&D system). The heart samples were obtained as for human VEGF-A. 
Capillary and arteriolar densities
Animals with myocardial infarction were euthanized 1 or 4 weeks after gene transfer. For the analysis of capillary density the sections were incubated with Griffonia Badeiraea Simplicifolia Isolectin B4 (GSL-I-B4, Vector Laboratories) followed by a second incubation with ABC Complex. Finally, capillaries were visualized by DAB with supplementation of 0.03% hydrogen peroxide. Capillaries were counted at a magnification of 400× taken by an LCD camera (Olympus, Japan) connected with a microscope. Ten fields of pictures around the injection site were taken and the capillary count was analyzed blinded with an image analysis program (Micro Image, Olympus). For the analysis of arteriolar density, lectin stained sections were incubated with primary antibody against α-actin (Sigma). Then rabbit anti-mouse secondary antibody (FITC, Dako) was used to visualize the blood vessels. Blood vessels stained around the injection site were counted under 200× magnification in a fluorescence microscope. All analyses were performed in a blinded manner.
Apoptosis assay
TUNEL assay was performed on frozen sections with an ApopTag Fluorescein in Situ Apoptosis Detection Kit (CHEMICON International, CA, USA) according to the manufacturer's specifications. Sections of heart tissue were treated with digoxigenin-dNTP and termial deoxynucleotidyl transferase followed by incubation with anti-digoxigenin conjugated with fluorescein. Counterstaining with DAPI was performed to visualize nuclei. Five fields of apoptotic positive cells were counted under 400× magnification in a blinded fashion. Two areas along the border of the myocardial infarction were analyzed: the injection site and the contralateral site of the myocardial infarction where no injection had been given.
Characterization of apoptotic cells
After TUNEL staining, slides were incubated with anti-α-sarcomeric actin to detect if the apoptotic cells were cardiomyocytes. Then fluorescent-labeled (TRITC) secondary antibody was added for visualization of cardiomyocytes.
Left ventricular function
Cardiac function was assessed by Tissue Doppler Echocardiography using a Vingmed Vivid 5 (Vingmed A/S, Norway) ultrasound system equipped with a 10 MHz transducer. Echocardiography was performed on the rats 3 days after ligation, and 4 weeks after gene transfer. Color Tissue Velocity Image was performed at the apical chamber view at frame rates close to 230 fps. The probe position was adjusted under the guidance of Pulsed Tissue Doppler to the maximum velocity of the mitral valve plane. The recording was obtained by positioning a sample volume in each basal septal left ventricular wall segment. Analysis was performed off-line from acquired cine loops with Echopac version 6.1. Peak systolic velocity was not measured due to unfavorable noise to signal ratio. Systolic velocity-time integral, a parameter for displacement of myocardium which is less noise dependent, was assessed from 2-3 beats to minimize the variability. The final value of regional systolic myocardial function was calculated as a mean value from 2-3 peak velocity-time integral at systole.
Statistical analysis
Data are presented as mean ± SEM. Comparison between the groups was made by means of Student's t-test, 1-way ANOVA followed by Fisher's PLSD test. Paired t-test was performed to compare the difference between values before and after treatment. Values were considered to be significantly different at a value of p ≤ 0.05. Fig. 2 shows AdhVEGF-A 165 and PhVEGF-A 165 doseresponse curves for VEGF-A expression. The highest adenoviral dose, 1 × 10 10 pfu, was associated with respiratory symptoms; the lowest dose, 1 × 10 9 pfu, was considered to have suboptimal hVEGF-A expression. The middle dose, 5 × 10 9 pfu, was then chosen as the optimal dose for further study. Of the plasmid doses the middle dose (40 μg), was chosen for its numerically highest hVEGF-A expression ( p b 0.01).
Results
hVEGF-A expression
AdhVEGF-A 165 induced substantially higher hVEGF-A expression than PhVEGF-A 165 in normal myocardium (17,280 ± 5467 versus 890 ± 452 pg/ml, p b 0.001, Fig. 3A) . In peri-infarction myocardium, AdhVEGF-A 165 and PhVEGF-A 165 expression was reduced to about 7% from that in the normal myocardium (938 ± 290 versus 60 ± 13 pg/ ml, p b 0.01). Still AdhVEGF-A 165 had a higher expression than PhVEGF-A 165 . hVEGF-A expression can also be visualized in myocardial tissue by immunohistochemistry (Fig. 3B) . Following intramyocardial delivery into the normal myocardium, ectopic expression of hVEGF-A in the kidney, lung, liver, and spleen was in the range of 2-5% of the myocardial expression. However, AdhVEGF-A 165 still induced higher hVEGF-A expression than PhVEGF-A 165 (318-503 for AdhVEGF-A 165 , 25-58 pg/ml for PhVEGF-A 165 , p b 0.01, Fig. 4 ).
Endogenous VEGF-A protein expression
For whole heart endogenous VEGF expression in normal myocardium, post myocardial infarction without or with injection of pLacZ or adLacZ did not differ (323 ± 18, 294 ± 10, 313 ± 70 and 272 ± 19 pg/ml, respectively). AdhVEGF-A 165 induced a higher level of rat VEGF-A expression (453 ± 47 pg/ml, p b 0.02) with a net increase of about 150 pg/ml being about 20% of the hVEGF-A expression. A similar pattern was seen for phVEGF-A 165 (348 ± 22 pg/ml), although the increment was not significant which might at least partly be due to dilution of endogenous rat VEGF from non-infarcted parts of the myocardium.
Arteriolar densities
One week after gene transfer, both PhVEGF-A 165 and AdhVEGF-A 165 induced about 80% higher arteriolar density compared with PLacZ (Fig. 5A, 28 ± 2 
Capillary densities
One week after gene transfer, both PhVEGF-A 165 and AdhVEGF-A 165 induced 17-18% higher capillary density compared with PLacZ (Fig. 5B, 2092 ± 104 for PhVEGF-A 165 , 2117 ± 91 for AdhVEGF-A 165 versus 1784 ± 41 capillaries/mm 2 for PLacZ, p b 0.05). After 1 month of treatment, there were no significant differences between any of the hVEGF-A 165 and the LacZ treated groups. AdLacZ showed a transient increase in capillary density at 1 week but not at 4 weeks. No hemangioma was observed in any of the treatment groups.
Apoptosis
Apoptotic cell numbers did not differ between groups in the non-injected peri-infarction region (5-7 cells/field). Plasmid and saline injection did not significantly increase the apoptotic cell number compared with the non-injected site, but both AdLacZ and AdhVEGF-A 165 induced a higher number of apoptotic cells (31 ± 6 and 24 ± 8 cells/ fields, respectively; p b 0.001, Fig. 6 ). Both AdLacZ and AdhVEGF-A 165 effected higher apoptotic cell numbers than PLacZ or PhVEGF-A 165 ( p b 0.02) . No significant difference between AdLacZ and AdhVEGF-A 165 was found.
Characterization of apoptotic cells
Immunofluorescence double staining showed some apoptotic cells were positive for anti-α-sarcomeric-actin, which is specific for α-cardiac muscle actin but does not cross react with smooth muscle cells (Fig. 7) .
Left ventricular function
Left ventricular velocity-time integral deteriorated with time around 30% with PLacZ treatments compared with baseline ( p b 0.05, Fig. 8 ), whereas it improved with 
Discussion
Intramyocardial AdhVEGF-A 165 gene transfer induced substantially higher hVEGF-A protein expression than PhVEGF-A 165 both in the myocardium and systemically. Unexpectedly, AdhVEGF-A 165 and PhVEGF-A 165 stimulated myocardial angiogenesis and improved cardiac function to a similar extent. AdhVEGF-A 165 induced significantly higher level of apoptosis than PhVEGF-A 165 .
This experiment compares angiogenic efficacy at the doses of plasmid and adenoviral vector expressing optimal amounts of hVEGF-A. Based on previous experience, maximum expression following intramyocardial application in animal models occurs between 24-48 h for plasmid and 6 days for adenoviral vector [14, 15] . AdhVEGF-A 165 induced a dosedependent increase in myocardial hVEGF-A expression. With the highest dose (1 × 10 10 pfu), however, signs of systemic infection appeared with respiratory symptoms of dyspnoea, pleural and pericardial effusions at autopsy. These adverse events were not observed with the middle dose (5 × 10 9 pfu). Therefore it was chosen as the optimal dose. Contrary to the adenoviral vector, plasmid transfer with the dose range used (20-60 μg) did not result in a linear dose-response curve. Due to its highest numerical mean expression, the middle dose (40 μg) was chosen as the optimal dose.
After gene transfer with the optimal doses chosen, hVEGF-A expression following the AdhVEGF-A 165 gene transfer was about 20 times higher than following PhVEGF-A 165 in the myocardium. This is consistent with previous studies [5, 6] . Interestingly, when injected into the peri-infarction region 7 days after the ligation of the coronary artery, both AdhVEGF-A 165 and PhVEGF-A 165 expressed only about 7% of that expressed in normal myocardium [16] . Reasons for the lower expression might be scar formation with less density of cardiac cells to be transfected by gene therapy. The gene delivered might also have had less spread in the peri-infarction area due to less cardiac systolic function and connective tissue formation after myocardial infarction.
The original hypothesis was that there should be a linear relation between the level of VEGF-A and the degree of angiogenesis. Thus a higher level of VEGF-A from AdhVEGF-A 165 transfer should have a more efficient angiogenic effect. Unexpectedly, AdhVEGF-A 165 and PhVEGF-A 165 induced a similar degree of angiogenesis during the 1-month follow-up.
It appears that the overexpressed hVEGF-A does only have a turn-on or ceiling effect at least with this experimental design with a rat myocardial infarction model. Higher hVEGF-A expression from adenovirus did not have any additive angiogenic effect. Angiogenesis depends on the balance between an array of stimulatory and inhibitory factors [17, 18] . It might be that such a balance only permits a small window for hVEGF-A overexpression to stimulate vessel growth. Thus only a small amount of VEGF would be needed to reach saturation of the angiogenesis in the periinfarction region. Although plasmid expressed less hVEGF-A, the VEGF amount might be sufficient for the angiogenic process.
AdLacZ also induced a transient increment of both capillaries and arterioles after 1 week of treatment. This suggests that the adenoviral infection might cause an inflammatory reaction [19] with secondary transient angiogenesis.
Gene transfer of VEGF induced more pronounced angiogenic effects at the arteriolar level than at the capillary level. This is consistent with previous studies [14, 15, 20] .
Tissue velocity assesses regional myocardial function and perfusion conditions [21, 22] . Similar improved ventricular displacement in both AdhVEGF-A 165 and PVEGF-A 165 suggested that increased mechanical function of the myocardium might be related to the increased perfusion. This indicates that the increased vessels induced by AdhVEGF-A 165 and PhVEGF-A 165 were functional.
TUNEL stained positive cells were present in low numbers in the non-injected peri-infarction area. A slight increase in number was observed for saline and plasmid injection, indicating little or no apoptotic effect. However, AdLacZ and AdhVEGF-A 165 caused a 5 to 8 fold increase in TUNEL stained cells compared with the non-injected area. It suggests that apoptosis might be induced by adenovirus in the injection region.
Adenovirus can modulate apoptosis [8, 9] . Adenovirus genes such as E1A and E4orf4 are pro-apoptotic whereas E1B and E3 are apoptosis inhibiting genes. In our experiment, we used the modified first generation adenovirus with deletion of E1 and E3. Still apoptosis was observed. VEGF is known to counteract apoptosis [9, 23] . AdhVEGF-A 165 showed a non-significant decrease in apoptosis compared with AdLacZ.
We determined apoptosis 7 days after gene transfer. At least some of the apoptotic cells were cardiomyocytes. An impairment of left ventricular function due to the iatrogenic myocardial apoptosis in the ischemic peri-infarction region cannot be excluded in the present study. But in fact, AdLacZ did not show any worsened cardiac function compared with PLacZ. Since adenovirus can induce inflammation [19] , the growth factors released by inflammatory cells can induce angiogenesis [24] . Consequently, a transient angiogenic effect was observed in the AdLacZ group. Increased vessel density can increase the perfusion thus might save the ischemic myocardium. Therefore although apoptosis was induced by adenovirus, the side effects might be overwhelmed by the salvage of myocardium induced by increased perfusion.
Ectopic hVEGF-A gene expression in different organs was found to be around 2-5% of that in the myocardium both with adenovirus and plasmid gene transfer. This indicates a similar mechanism of systemic leakage of adenovirus and plasmid vectors from local myocardial delivery. However, AdhVEGF-A 165 still induced much higher hVEGF-A expression than plasmid.
In the myocardial infarction model used, the therapeutic window for myocardial angiogenesis appears to be saturated already with the hVEGF-A expression induced by plasmid gene transfer. As adenovirus induces higher local expression of hVEGF-A, it also induces higher systemic expression levels concomitant with potential undesirable effects induced by hVEGF-A as well as tissue inflammation and apoptosis. Thus if there is a therapeutic window with a ceiling effect and AdhVEGF-A 165 should be used as angiogenic stimulator, the dose can be reduced to decrease side effects with retained angiogenic effect.
In conclusion, in this myocardial infarction model adenoviral gene transfer has no obvious angiogenic advantage over PhVEGF-A 165 but more side effects. This indicates that PhVEGF-A 165 might be more applicable than AdhVEGF-A 165 for therapeutic angiogenesis.
